Details of the Drug Combination

General Information of Drug Combination (ID: DC6BCOR)

Drug Combination Name

Harmine 2-(1H-indol-3-yl)-N,N-dimethylethanamine

Indication

Disease Entry	Status	REF
Emotions	Phase 1	[1]

Component Drugs

Harmine DMPA5WD

2-(1H-indol-3-yl)-N,N-dimethylethanamine DMR9Q4Y

Small molecular drug

2D MOL

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Harmine

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[2]

Harmine Interacts with 4 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2)	TT84OS6	DYRK2_HUMAN	Inhibitor	[4]
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Inhibitor	[2]
Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)	TTSBVFO	DYR1A_HUMAN	Inhibitor	[4]
Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3)	TTV4EX0	DYRK3_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

Harmine Interacts with 23 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Decreases Activity	[5]
Amine oxidase A (MAOA)	OT8NIWMQ	AOFA_HUMAN	Decreases Activity	[6]
Transcription factor E2F8 (E2F8)	OTQKZGFP	E2F8_HUMAN	Increases Expression	[7]
Nuclear factor of activated T-cells, cytoplasmic 1 (NFATC1)	OT4TMERS	NFAC1_HUMAN	Affects Localization	[7]
G1/S-specific cyclin-E2 (CCNE2)	OTBBUKQQ	CCNE2_HUMAN	Increases Expression	[7]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Increases Expression	[7]
Insulin (INS)	OTZ85PDU	INS_HUMAN	Increases Expression	[7]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Increases Expression	[7]
M-phase inducer phosphatase 1 (CDC25A)	OTSLKKCO	MPIP1_HUMAN	Increases Expression	[7]
M-phase inducer phosphatase 3 (CDC25C)	OTPQI71S	MPIP3_HUMAN	Increases Expression	[7]
Cyclin-dependent kinase inhibitor 2A (CDKN2A)	OTN0ZWAE	CDN2A_HUMAN	Decreases Expression	[7]
Cyclin-dependent kinase 4 inhibitor B (CDKN2B)	OTAG24N1	CDN2B_HUMAN	Decreases Expression	[7]
Cyclin-dependent kinase inhibitor 1C (CDKN1C)	OTASTJ3Q	CDN1C_HUMAN	Decreases Expression	[7]
Pancreas/duodenum homeobox protein 1 (PDX1)	OTX1DKRA	PDX1_HUMAN	Increases Expression	[7]
Cyclin-A1 (CCNA1)	OTX4HD45	CCNA1_HUMAN	Increases Expression	[7]
Transcription factor E2F1 (E2F1)	OTLKYBBC	E2F1_HUMAN	Increases Expression	[7]
Forkhead box protein M1 (FOXM1)	OT5887KR	FOXM1_HUMAN	Increases Expression	[7]
Nuclear factor of activated T-cells, cytoplasmic 3 (NFATC3)	OTYOORME	NFAC3_HUMAN	Affects Localization	[7]
Nuclear factor of activated T-cells, cytoplasmic 2 (NFATC2)	OTK5T6HZ	NFAC2_HUMAN	Affects Localization	[7]
Transcription factor E2F2 (E2F2)	OTO75RM7	E2F2_HUMAN	Increases Expression	[7]
Nuclear factor of activated T-cells, cytoplasmic 4 (NFATC4)	OTTDCUAO	NFAC4_HUMAN	Affects Localization	[7]
Transcription factor MafA (MAFA)	OTBCA105	MAFA_HUMAN	Increases Expression	[7]
Transcription factor E2F7 (E2F7)	OTWW358N	E2F7_HUMAN	Increases Expression	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 23 DOT(s)

Indication(s) of 2-(1H-indol-3-yl)-N,N-dimethylethanamine

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[3]

2-(1H-indol-3-yl)-N,N-dimethylethanamine Interacts with 3 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
5-HT 6 receptor (HTR6)	TTJS8PY	5HT6R_HUMAN	Inhibitor	[8]
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Inhibitor	[8]
Opioid receptor sigma 1 (OPRS1)	TT5TPI6	SGMR1_HUMAN	Inhibitor	[8]
------------------------------------------------------------------------------------

2-(1H-indol-3-yl)-N,N-dimethylethanamine Interacts with 4 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
5-hydroxytryptamine receptor 2A (HTR2A)	OTWXJX0M	5HT2A_HUMAN	Decreases Response To Substance	[9]
Flavin-containing monooxygenase 3 (FMO3)	OT1G2EV3	FMO3_HUMAN	Increases Metabolism	[10]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Increases Metabolism	[10]
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Increases Metabolism	[10]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04716335) Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects
2	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 141).
4	Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199.
5	Transcriptional and posttranslational inhibition of dioxin-mediated induction of CYP1A1 by harmine and harmol. Toxicol Lett. 2012 Jan 5;208(1):51-61.
6	In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks. Toxicol Lett. 2017 Apr 15;272:84-93.
7	A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat Med. 2015 Apr;21(4):383-8. doi: 10.1038/nm.3820. Epub 2015 Mar 9.
8	Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994 Feb;51(2):85-97.
9	Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies. Pharmacogenomics J. 2006 Jan-Feb;6(1):42-51. doi: 10.1038/sj.tpj.6500342.
10	What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse?. Toxicol Lett. 2016 Sep 6;258:55-70. doi: 10.1016/j.toxlet.2016.06.013. Epub 2016 Jun 15.